Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Susceptibility tensor imaging (STI) of the brain.
Neuron-specific SALM5 limits inflammation in the CNS via its interaction with HVEM.
A monoclonal natural human IgM protects axons in the absence of remyelination.
Moving Targets for Hematopoietic Stem Cell Transplantation for Multiple Sclerosis.
European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis.
The role of global and regional gray matter volume decrease in multiple sclerosis.
Oligodendrogliopathy in Multiple Sclerosis: Low Glycolytic Metabolic Rate Promotes Oligodendrocyte Survival.
Diplomatic Assistance: Can Helminth-Modulated Macrophages Act as Treatment for Inflammatory Disease?
The effects of diet on the severity of central nervous system disease: One part of lab-to-lab variability.
12-oxo-phytodienoic acid, a plant-derived oxylipin, attenuates lipopolysaccharide-induced inflammation in microglia.
Rare MEFV variants are not associated with risk to develop multiple sclerosis and severity of disease.
Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.
Biogen slips as FDA extends review of MS drug
Fingolimod modulates multiple neuroinflammatory markers in a mouse model of Alzheimer's disease.
Magnetic resonance imaging of myelin using ultrashort Echo time (UTE) pulse sequences: Phantom, specimen, volunteer and multiple sclerosis patient studies.
Development of Guillain-Barré syndrome in a patient with multiple sclerosis during treatment with glatiramer acetate.
Clinically isolated syndromes: a new oligoclonal band test accurately predicts conversion to MS.
Brain-gut axis and pentadecapeptide BPC 157. Theoretical and practical implications.
Eosinophilic Fasciitis-like Disorder Developing in the Setting of Multiple Sclerosis Therapy.
Teriflunomide attenuates immunopathological changes in the dark agouti rat model of experimental autoimmune encephalomyelitis.
A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis.
New data reinforce efficacy of TECFIDERA® (dimethyl fumarate) in MS patients with high disease activity
Management of multiple sclerosis and the integration of related specialty pharmacy programs within health systems.
Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.
The Charcot Lecture | Beating MS: A story of B cells, with twists and turns.

Pages